Journal of Basic and Clinical Pathophysiology

Journal of Basic and Clinical Pathophysiology

The effect of paeonol on motor deficits and depressive and anxiety-like behavior in cuprizone-induced model of multiple sclerosis

Document Type : Research Paper

Authors
Soosan Pourmohammadi 1
Zahra Kiasalari 2
Mohsen Khalili 2
Mehrdad Roghani 2
1 Department of Biology, Faculty of Basic Sciences, Shahed University, Tehran, Iran
2 Neurophysiology Research Center, Shahed University, Tehran, Iran
10.22070/jbcp.2021.14744.1146
Abstract
Background and Objective: Patients with multiple sclerosis (MS) exhibit varying degrees of motor deficits, anxiety, and depression. Chronic oral cuprizone through evoking demyelination process is generally used to induce a model of MS to assess potential efficacy of promising therapeutics. Paeonol is a phenol compound with beneficial anti-inflammatory and protective effects. This study was conducted to investigate the effect of paeonol on motor deficits and depressive and anxiety-like behavior using open field, elevated plus maze, and tail suspension test in C57Bl/6 mice.
Materials and Methods: Mice received oral cuprizone at a dose of 400 mg/kg for 6 weeks and paeonol was given orally at doses of 25 or 100 mg/kg/day from the second week for next five weeks. To assess motor function and depressive and anxiety-like behavior, open field task, tail suspension test (TST), and elevated-plus maze (EPM) test were used, respectively. Data were analyzed by one-way ANOVA and Tukey post-test with significance level < 0.05.
Results: Paeonol administration to cuprizone group at the higher dose of 100 mg/kg improved locomotor activity and motor coordination as was evident by higher line crossing and an increase in the spent time in the center. In addition, paeonol treatment of cuprizone group significantly reduced spent time in the open arms of elevated-plus maze and also decreased immobility time in tail suspension task.
Conclusion: This study showed reversal effects of paeonol regarding motor deficits and depressive and anxiety-like behavior in cuprizone-induced model of MS.
Keywords
Cuprizone
Paeonol
Motor deficits
Anxiety
Depression
  1. Fleming KM, Coote SB, Herring MP. Home-based Pilates for symptoms of anxiety, depression and fatigue among persons with multiple sclerosis: An 8-week randomized controlled trial. Multiple Sclerosis 2021:13524585211009216.
  2. Janshen L, Santuz A, Arampatzis A. Muscle Synergies in Patients With Multiple Sclerosis Reveal Demand-Specific Alterations in the Modular Organization of Locomotion. Frontiers in Human Neuroscience 2020; 14:593365.
  3. Shaygannejad V, Mirmosayyeb O, Nehzat N, Ghajarzadeh M. Fear of relapse, social support, and psychological well-being (depression, anxiety, and stress level) of patients with multiple sclerosis (MS) during the COVID-19 pandemic stage. Neurological Sciences 2021:1-4.
  4. Bahathig A, Alblowi MA, Alhilali AA, AlJasim BS, Alhelow M, Aldakheel H, et al. The prevalence and association of depression and anxiety with multiple sclerosis in riyadh, saudi arabia: a cross-sectional study. Cureus 2020; 12(12):e12389.
  5. Tauil CB, Rocha-Lima AD, Ferrari BB, Silva FMD, Machado LA, Ramari C, et al. Depression and anxiety disorders in patients with multiple sclerosis: association with neurodegeneration and neurofilaments. Brazilian Journal of Medical and Biological Research 2021; 54(3):e10428.
  6. Kołtuniuk A, Rosińczuk J. The Levels of Depression, Anxiety, Acceptance of Illness, and Medication Adherence in Patients with Multiple Sclerosis - Descriptive and Correlational Study. International Journal of Medical Sciences 2021;18(1):216-25.
  7. Ramachandhiran D, Vinothkumar V, Babukumar S. Paeonol exhibits anti-tumor effects by apoptotic and anti-inflammatory activities in 7,12-dimethylbenz(a)anthracene induced oral carcinogenesis. Biotechnic and Histochemistry 2019;94(1):10-25.
  8. Chen B, Ning M, Yang G. Effect of paeonol on antioxidant and immune regulatory activity in hepatocellular carcinoma rats. Molecules 2012;17(4):4672-83.
  9. Zhou J, Zhou L, Hou D, Tang J, Sun J, Bondy SC. Paeonol increases levels of cortical cytochrome oxidase and vascular actin and improves behavior in a rat model of Alzheimer's disease. Brain Research 2011;1388:141-7.
  10. Zhang D, Wu J, Wu J, Zhang S. Paeonol Induces Protective Autophagy in Retinal Photoreceptor Cells. Frontiers in Pharmacology 2021;12:667959-.
  11. Zhu XL, Chen JJ, Han F, Pan C, Zhuang TT, Cai YF, et al. Novel antidepressant effects of Paeonol alleviate neuronal injury with concomitant alterations in BDNF, Rac1 and RhoA levels in chronic unpredictable mild stress rats. Psychopharmacology 2018;235(7):2177-91.
  12. Tao W, Wang H, Su Q, Chen Y, Xue W, Xia B, et al. Paeonol attenuates lipopolysaccharide-induced depressive-like behavior in mice. Psychiatry Research 2016;238:116-21.
  13. Zhang H, Geng X, Li Z, Li Y, Xu K, Wu H, et al. Paeonol at Certain Doses Alleviates Aggressive and Anxiety-Like Behaviours in Two Premenstrual Dysphoric Disorder Rat Models. Frontiers in Psychiatry 2020; 11:295.
  14. Mi XJ, Chen SW, Wang WJ, Wang R, Zhang YJ, Li WJ, et al. Anxiolytic-like effect of paeonol in mice. Pharmacology Biochemistry and Behavior 2005; 81(3):683-7.
  15. Abo Taleb HA, Alghamdi BS. Neuroprotective Effects of Melatonin during Demyelination and Remyelination Stages in a Mouse Model of Multiple Sclerosis. Journal of Molecular Neuroscience 2020; 70(3):386-402.
  16. Zhen W, Liu A, Lu J, Zhang W, Tattersall D, Wang J. An Alternative Cuprizone-Induced Demyelination and Remyelination Mouse Model. ASN Neuro 2017; 9(4):1759091417725174.
  17. Niiyama T, Kuroiwa M, Yoshioka Y, Kitahara Y, Shuto T, Kakuma T, et al. Sex Differences in Dendritic Spine Formation in the Hippocampus and Animal Behaviors in a Mouse Model of Hyperthyroidism. Frontiers in Cellular Neuroscience 2020; 14:268.
  18. Liu H, Zhai J, Wang B, Fang M. Olig2 Silence Ameliorates Cuprizone-Induced Schizophrenia-Like Symptoms in Mice. Medical Science Monitor 2017; 23:4834-40.
  19. Sun Z, Jiang T, Wu Y, Ma C, He Y, Yang J. Low Field Magnetic Stimulation Ameliorates Schizophrenia-Like Behavior and Up-Regulates Neuregulin-1 Expression in a Mouse Model of Cuprizone-Induced Demyelination. Frontiers in Psychiatry 2018;9:675-.
  20. Franco-Pons N, Torrente M, Colomina MT, Vilella E. Behavioral deficits in the cuprizone-induced murine model of demyelination/remyelination. Toxicology Letters 2007;169(3):205-13.
  21. Nave KA. Myelination and the trophic support of long axons. Nature Reviews Neuroscience 2010;11(4):275-83.
  22. Yang H-J, Wang H, Zhang Y, Xiao L, Clough RW, Browning R, et al. Region-specific susceptibilities to cuprizone-induced lesions in the mouse forebrain: Implications for the pathophysiology of schizophrenia. Brain Research 2009;1270:121-30.
  23. Franco-Pons N, Torrente M, Colomina MT, Vilella E. Behavioral deficits in the cuprizone-induced murine model of demyelination/remyelination. Toxicology Letters 2007;169(3):205-13.
  24. Yang L, Su Y, Guo F, Zhang H, Zhao Y, Huang Q, et al. Deep rTMS Mitigates Behavioral and Neuropathologic Anomalies in Cuprizone-Exposed Mice Through Reducing Microglial Proinflammatory Cytokines. Frontiers in Integrative Neuroscience 2020; 14:556839.
  25. Shao Y, Ding J, He QX, Ma QR, Liu Q, Zhang C, et al. Effect of Sox10 on remyelination of the hippocampus in cuprizone-induced demyelinated mice. Brain and Behavior 2020; 10(6):e01623.
  26. Mitra NK, Xuan KY, Teo CC, Xian-Zhuang N, Singh A, Chellian J. Evaluation of neuroprotective effects of alpha-tocopherol in cuprizone-induced demyelination model of multiple sclerosis. Research in Pharmaceutical Sciences 2020; 15(6):602-11.
  27. Adilijiang A, Guan T, He J, Hartle K, Wang W, Li X. The Protective Effects of Areca catechu Extract on Cognition and Social Interaction Deficits in a Cuprizone-Induced Demyelination Model. Evidence-Based Complementary and Alternative Medicine 2015; 2015:426092.
  28. Shi X, Chen YH, Liu H, Qu HD. Therapeutic effects of paeonol on methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid-induced Parkinson's disease in mice. Molecular Medicine Reports 2016; 14(3):2397-404.
Journal of Basic and Clinical Pathophysiology
Volume 9, Issue 2
November 2021
Pages 49-54